Navigation Links
BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year
Date:9/8/2009

EXTON, Pa., Sept. 8 /PRNewswire/ -- For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

Over the past five years, BioTrends has become an established player in the field of syndicated market research in the healthcare sector. "In spite of industry cut-backs, our business has flourished in the past two years. We believe this is due to our unique offering - high quality primary market research conducted in specialty pharmaceutical markets and shared across multiple clients which, in turn, provides a cost effective alternative to traditional single client proprietary projects," says Sharon Funk, Vice President of Market Research Services at BioTrends.

Originally focused entirely in Nephrology, BioTrends now offers syndicated reports in multiple specialties and therapeutic categories including Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Gout/Hyperuricemia, Inflammatory Bowel Disease, and Lupus. The 2010 Publication Plan, published earlier this week, includes over 50 planned publications with new categories such as Fibromyalgia, Hepatitis, Macular Degeneration and Hypertension.

"We expect 2010 to be another exciting year for BioTrends as we expand into new therapeutic and new geographic areas. We are currently in the process of identifying savvy industry professionals to join the BioTrends team in 2010 to help us capitalize on the tremendous demand for our products and services" says Jennifer Robinson, Founder and President of BioTrends.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To learn more, please contact us at (610) 363-3872 or visit us at www.bio-trends.com

About the Philly 100

For more information on the Philadelphia 100, visit www.philadelphia100.com.

CONTACT: Jennifer Robinson of BioTrends Research Group, Inc., +1-610-363-3872, jrobinson@bio-trends.com


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
2. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
3. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
5. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
7. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
8. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
10. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
Breaking Biology Technology:
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
Breaking Biology News(10 mins):